Cited by 1,073SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Open access

Pallesen, Jesper, Wang, Nianshuang, Corbett, Kizzmekia S., Wrapp, Daniel, Kirchdoerfer, Robert N., Turner, Hannah L., Cottrell, Christopher A., Becker, Michelle M., Wang, Lingshu, Shi, Wei, Kong, Wing-Pui, Andres, Erica L., Kettenbach, Arminja N., Denison, Mark R., Chappell, James D., Graham, Barney S., Ward, Andrew B., McLellan, Jason S.·2017·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1707304114PMC PMC5584442

Open this paper in CoChat — free account Open PDF

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus that since its emergence in 2012 has caused outbreaks in human populations with case-fatality rates of ∼36%. As in other coronaviruses, the spike (S) glycoprotein of MERS-CoV mediates receptor recognition and membrane fusion and is the primary target of the humoral immune response during infection. Here we use structure-based design to develop a generalizable strategy for retaining coronavirus S proteins in the antigenically optimal prefusion conformation and demonstrate that our engineered immunogen is able to elicit high neutralizing antibody titers against MERS-CoV. We also determined high-resolution structures of the trimeric MERS-CoV S ectodomain in complex with G4, a stem-directed neutralizing antibody. The structures reveal that G4 recognizes a glycosylated loop that is variable among coronaviruses and they define four conformational states of the trimer wherein each receptor-binding domain is either tightly packed at the membrane-distal apex or rotated into a receptor-accessible conformation. Our studies suggest a potential mechanism for fusion initiation through sequential receptor-binding events and provide a foundation for the structure-based design of coronavirus vaccines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.1707304114

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 46,047
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677
RELION: Implementation of a Bayesian approach to cryo-EM structure determination
Scheres, S. H. W. (2012) · Journal of Structural Biology · doi:10.1016/j.jsb.2012.09.006 · Cited by 5,446
How good are my data and what is the resolution?
Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,743
Comparative Protein Structure Modeling Using MODELLER
Webb, B., & Šali, A. (2016) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.3 · Cited by 4,404
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
ConSurf 2016: An improved methodology to estimate and visualize evolutionary conservation in macromolecules
Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., & Ben-Tal, N. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw408 · Cited by 3,163

Show all 89 references

Sorted by citations

Items 801–900 of 1,000

Safe plant Hsp90 adjuvants elicit an effective immune response against SARS-CoV2-derived RBD antigen
Ramos-Duarte, V. A., Orlowski, A., de Giusti, C. J., Corigliano, M. G., Legarralde, A., Morales, L. F. M., Atela, A., Sánchez, M. A., Sander, V. A., Angel, S. O., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.036 · Cited by 4
DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice
Shen, X., Wang, S., Hao, Y., Fu, Y., Ren, L., Li, D., Tang, W., Li, J., Chen, R., Zhu, M., et al. (2024) · Virologica Sinica · doi:10.1016/j.virs.2024.05.005 · Cited by 4
Determination of human COVID‐19 total antibodies in serum using a time‐resolved fluorescence immunoassay
Xu, Y., Chen, C., Lai, H., He, Y., Guo, G., Feng, J., & Li, L. (2021) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2219 · Cited by 4
Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
Xiang, R., Wang, Y., Wang, L., Deng, X., Huo, S., Jiang, S., & Yu, F. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.12.015 · Cited by 4
Self-citation
The Pathophysiology of Virulence of the COVID-19Preprint
Soto, J. D., Hakim, S. T., & Boyd, F. (2020) · Preprints.org · doi:10.20944/preprints202004.0077.v2 · Cited by 4
SARS-CoV-2 comprehensive receptor profiling: mechanistic insight to drive new therapeutic strategiesPreprint
Brockbank, S., Soden, J., Faba-Rodriguez, R., Ribeiro, L. R., Geh, C., Thomas, H., Delight, J., Coverley, L. C., Abbott, W. M., & Freeth, J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.11.434937 · Cited by 5
Receptor binding may directly activate the fusion machinery in coronavirus spike glycoproteinsPreprint
Wang, Y., Fallon, L., Raguette, L. E., Budhan, S., Belfon, K. A. A., Stepanenko, D., Helbock, S., Varghese, S., & Simmerling, C. L. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.10.443496 · Cited by 4
Diversity of Coronavirus ReceptorsPreprint
Ghosh, P., Jayaram, S., Patwardhan, D., Marimuthu, S., Lenehan, P. J., Venkatakrishnan, A., Hughes, T. K., Zemmour, D., Anand, P., & Soundararajan, V. (2021) · Preprints.org · doi:10.20944/preprints202108.0071.v1 · Cited by 4
Conformational dynamics and allosteric modulation of the SARS-CoV-2 spikePreprint
Díaz-Salinas, M. A., Li, Q., Ejemel, M., Yurkovetskiy, L., Luban, J., Shen, K., Wang, Y., & Munro, J. B. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.29.466470 · Cited by 4
Heterologous booster immunization with SARS-CoV-2 spike protein after mRNA vaccine elicits durable and broad antibody responsesPreprint
Takano, T., Sato, T., Kotaki, R., Moriyama, S., Shinoda, M., Kabasawa, K., Shimada, N., Kousaka, M., Adachi, Y., Onodera, T., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2014078/v1 · Cited by 4
Structural dynamics in the evolution of SARS-CoV-2 spike glycoproteinPreprint
Calvaresi, V., Wrobel, A. G., Toporowska, J., Hammerschmid, D., Doores, K. J., Bradshaw, R. T., Parsons, R. B., Benton, D. J., Roustan, C., Reading, E., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2049401/v1 · Cited by 4
A critical residue in a conserved RBD epitope determines neutralization breadth of pan-sarbecovirus antibodies with recurring YYDRxxG motifs
Stein, S. C., Ssebyatika, G. L., Benecke, T., Stroh, L. J., Rajak, M. K., Vollmer, B., Menz, S., Waldmann, J.-Y., Tipp, S. N., Ochulor, O., et al. (2025) · mBio · doi:10.1128/mbio.00606-25 · Cited by 3
Cross-neutralization ability of anti-MERS-CoV monoclonal antibodies against a variety of merbecoviruses
Pan, L., Kaku, Y., Tolentino, J. E., Kosugi, Y., & Sato, K. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1593095 · Cited by 3
Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial
Batmunkh, T., Neal, E. F. G., Amraa, O., Mazarakis, N., Altangerel, B., Avaa, N., Batbayar, L., Batsukh, K., Bright, K., Burentogtokh, T., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127840 · Cited by 3
COVID-19 in retrospect: Public health lessons from a global crisis
Bratzler, D. W. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.10.008 · Cited by 4
Structural features of sensory two component systems: a synthetic biology perspective
Nieves, M., Buschiazzo, A., & Trajtenberg, F. (2023) · Biochemical Journal · doi:10.1042/bcj20210798 · Cited by 3
Impfungen als Schlüssel der Pandemiebewältigung
Le, N. H., Hillus, D., Tober‐Lau, P., & Sander, L. E. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2124-2366 · Cited by 3
A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine
Pather, S., Charpentier, N., van den Ouweland, F., Rizzi, R., Finlayson, A., Salisch, N. C., Muik, A., Lindemann, C., Khanim, R., Abdul-Jawad, S., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126165 · Cited by 3
Lessons Learned from SARS-CoV and MERS-CoV: Preparation for SARS-CoV-2 induced COVID-19
Hong, S., Park, H., & Nam, J. (2020) · Journal of Bacteriology and Virology · doi:10.4167/jbv.2020.50.2.076 · Cited by 4
Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses
Vzorov, A. N., Samokhvalov, E. I., Chebanenko, V. V., Scheblyakov, D. V., & Al, G. (2021) · Molecular Biology · doi:10.1134/s0026893321030158 · Cited by 3
Grand Challenges in Vaccine Delivery: Lessons Learned From the COVID-19 Vaccine Rollout
Foged, C. (2022) · Frontiers in Drug Delivery · doi:10.3389/fddev.2022.964298 · Cited by 3
COVID-19 Vaccine-Induced Lichenoid Eruptions—Clinical and Histopathologic Spectrum in a Case Series of Fifteen Patients with Review of the Literature
Sapadin, Y. K., Mermelstein, E., Phelps, R. G., Basler, C. F., Tufariello, J. M., & Lebwohl, M. (2023) · Vaccines · doi:10.3390/vaccines11020438 · Cited by 3
Soluble SARS‐CoV ‐2 RBD and human ACE2 peptidase domain produced in Drosophila S2 cells show functions evoking virus–cell interface
Carrión, F., Rammauro, F., Olivero‐Deibe, N., Fló, M., Portela, M. M., Lima, A. E., Durán, R., Pritsch, O., & Bianchi, S. (2023) · Protein Science · doi:10.1002/pro.4721 · Cited by 3
A Critical Assessment of COVID-19 Genomic Vaccines
Sabbah, D. A., Hajjo, R., & Sunoqrot, S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230825094341 · Cited by 4
High-Accuracy Prediction of Stabilizing Surface Mutations to the Three-Helix Bundle, UBA(1), with EmCAST
Rothfuss, M. T., Becht, D. C., Zeng, B., McClelland, L. J., Yates-Hansen, C., & Bowler, B. E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04966 · Cited by 4
Novel Multi-Antigen Orf-Virus-Derived Vaccine Elicits Protective Anti-SARS-CoV-2 Response in Monovalent and Bivalent Formats
Burri, D. J., Renz, L., Mueller, M., Pagallies, F., Klinkhardt, U., Amann, R., & Derouazi, M. (2024) · Vaccines · doi:10.3390/vaccines12050490 · Cited by 3
Exploring the therapeutic potential of Terminalia ferdinandiana (Kakadu Plum) in targeting obesity-induced Type 2 diabetes and chronic inflammation: An in silico and experimental study
Morshed, M. N., Awais, M. U., Akter, R., Park, J., Ling, L., Kong, B. M., Yang, D., Yang, D. U., Kang, S. C., & Jung, S.-K. (2024) · South African Journal of Botany · doi:10.1016/j.sajb.2024.05.056 · Cited by 3
Engineering a cleaved, prefusion-stabilized influenza B virus hemagglutinin by identification and locking of all six pH switches
Juraszek, J., Milder, F. J., Yu, X., Blokland, S., van Overveld, D., Abeywickrema, P. D., Tamara, S., Sharma, S. P., Rutten, L., Bakkers, M. J. G., et al. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae462 · Cited by 3
Development of multivalent SARS-CoV-2 virus-like particle vaccine candidates
Bezeljak, U., Jerman, A., Kobal, T., Birsa, E., Kosmač, M. L., Žiberna, R., Lokar, K., Janež, N., Ravlić, S., Halassy, B., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127394 · Cited by 3
The impact of high-resolution structural data on stemming the COVID-19 pandemic
Cox, R. M., & Plemper, R. K. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.05.005 · Cited by 3
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine
Estephan, L., Liu, L. T.-C., Lien, C.-E., Smith, E. R., Gurwith, M., & Chen, R. T. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.083 · Cited by 3
CRISPro: An Automated Pipeline for Protein Conformation Stabilization by Proline
Rawi, R., Shen, C., Kwong, P. D., & Chuang, G. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00592 · Cited by 3
SARS-CoV-2 mutations and where to find them: an in silico perspective of structural changes and antigenicity of the spike protein
Gonçalves, R. L., Leite, T. C. R., Dias, B. D. P., Caetano, C. C. D. S., de Souza, A. C. G., Batista, U. D. S., Barbosa, C. C., Reyes‐Sandoval, A., Coelho, L. F. L., & Silva, B. D. M. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1844052 · Cited by 4
Prefusion spike protein stabilization through computational mutagenesis
Zhang, D. Y., Wang, J., & Dokholyan, N. V. (2020) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26025 · Cited by 3
Multi-epitope Based Peptide Vaccine Design Using Three Structural Proteins (S, E, and M) of SARS-CoV-2: An In Silico ApproachPreprint
Roy, A. S., Tonmoy, M. I. Q., Fariha, A., Hami, I., Afif, I. K., Munim, M. A., Alam, M. R., & Hossain, M. S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.13.149880 · Cited by 5
Double Lock of a Potent Human Monoclonal Antibody against SARS-CoV-2Preprint
Zhu, L., Deng, Y., Zhang, R., Cui, Z., Sun, C., Fan, C., Xing, X., Huang, W., Chen, Q., Zhang, N., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.24.393629 · Cited by 3
Self-citation
Computational study of the strong binding mechanism of SARS-CoV-2 spike and ACE2Preprint
Peng, C., Zhu, Z., Shi, Y., Wang, X., Mu, K., Yang, Y., Zhang, X., Xu, Z., & Zhu, W. (2020) · ChemRxiv · doi:10.26434/chemrxiv.11877492 · Cited by 3
Selectomic and Evolvability Analyses of the Highly Pathogenic Betacoronaviruses SARS-CoV-2, SARS-CoV, and MERS-CoVPreprint
May, M., Rostama, B., & Relich, R. F. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.05.078956 · Cited by 3
Decreased efficacy of a COVID-19 vaccine due to mutations present in early SARS-CoV-2 variants of concernPreprint
Weidenbacher, P. A. B., Friedland, N., Sanyal, M., Morris, M. K., Do, J., Hanson, C. V., & Kim, P. S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.27.546764 · Cited by 5
Characterization of SARS-CoV-2 Convalescent Patients’ Serological Repertoire Reveals High Prevalence of Iso–RBD AntibodiesPreprint
Curtis, N. C., Shin, S., Hederman, A. P., Connor, R. I., Wieland‐Alter, W., Ionov, S., Boylston, J. A., Rose, J., Sakharkar, M., Dorman, D. B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.08.556349 · Cited by 4
The Interplay of Furin Cleavage and D614G in Modulating SARS-CoV-2 Spike Protein DynamicsPreprint
Shoemaker, S. R., Luo, M., Dam, K.-M. A., Pak, J. E., Hoffmann, M. A. G., & Marqusee, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.27.635166 · Cited by 3
Virus glycoprotein nanodisc platform for vaccine designPreprint
Rantalainen, K. I., Liguori, A., Ozorowski, G., Flynn, C., Steichen, J. M., Swanson, O. M., Madden, P. J., Baboo, S., Phulera, S., Gharpure, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.02.651272 · Cited by 3
Self-citation
Structure‐based design of a Plasmodium vivax Duffy‐binding protein immunogen focuses the antibody response to functional epitopes
Dickey, T. H., McAleese, H., Salinas, N. D., Lambert, L., & Tolia, N. H. (2024) · Protein Science · doi:10.1002/pro.5095 · Cited by 2
Adoptive transfer of natural killer cells in therapeutic treatment of COVID-19 patients
Alamri, A. (2025) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-025-00670-2 · Cited by 2
Cetacean coronavirus spikes highlight S glycoprotein structural plasticity
Hulswit, R. J. G., Shamorkina, T. M., van der Lee, J., Rosman, F., Wetzels, L. S., van Kuppeveld, F. J. M., Snijder, J., Bosch, B., & Hurdiss, D. L. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1013855 · Cited by 2
Rabies glycoprotein engineering for improved stability and expression
English, S., Fedosyuk, S., Orliacq, F., Tem, V., Taylor, W., Alam, N., Xiang, Z., Thorley, L., López‐Camacho, C., Ertl, H. C. J., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127541 · Cited by 2
Rational design of therapeutic RNA molecules
Fang, F., & Wei, B. (2025) · Trends in Chemistry · doi:10.1016/j.trechm.2025.09.016 · Cited by 2
Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial
Chappell, K. J., Mordant, F. L., Amarilla, A. A., Modhiran, N., Liang, B., Li, Z., Lackenby, J. A., Jaberolansar, N., O’Donnell, J. S., Kienzle, V., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf568 · Cited by 2
Virus glycoprotein nanodisc platform for vaccine analytics
Rantalainen, K. I., Liguori, A., Ozorowski, G., Flynn, C. T., Steichen, J. M., Swanson, O. M., Madden, P. J., Baboo, S., Phulera, S., Gharpure, A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68985-1 · Cited by 5
Self-citation
Hydrogen–Deuterium Exchange Mass Spectrometry Reveals an Antibody-Induced Allosteric Pathway Driving SARS-CoV-2 Spike Trimer Disassembly
Luo, Y., Liu, B., Liu, R., Chen, Q., Xiong, X., & Li, H. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c18784 · Cited by 3
Heterologous betacoronavirus spike immunization in non-human primates elicits antibodies that neutralize both sarbeco- and merbecoviruses
Dueker, K., Capozzola, T., Feng, Z., Lin, R. N., Hurtado, J., Bangaru, S., Yuan, M., Beutler, N., Garcia, E., He, W.-T., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117439 · Cited by 2
Self-citation
Systemic Neutralizing Antibodies and Local Immune Responses Are Critical for the Control of SARS-CoV-2
Chandrasekar, S., Phanse, Y., Riel, M., Hildebrand, R. E., Hanafy, M., Osorio, J. E., Abdelgayed, S. S., & Talaat, A. M. (2022) · Viruses · doi:10.3390/v14061262 · Cited by 2
Single Amino Acid Substitution in the Receptor Binding Domain of Spike Protein Is Sufficient To Convert the Neutralization Profile between Ethiopian and Middle Eastern Isolates of Middle East Respiratory Coronavirus
Sugimoto, S., Kakizaki, M., Kawase, M., Kawachi, K., Ujike, M., Kamitani, W., Sentsui, H., & Shirato, K. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04590-22 · Cited by 2
Development and evaluation of vaccination strategies for addressing the continuous evolution SARS-CoV-2 based on recombinant trimeric protein technology: Potential for cross-neutralizing activity and broad coronavirus response
Du, P. F., Li, N., Tang, S., Zhou, Z., Liu, Z., Wang, T., Li, J., Zeng, S., & Chen, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34492 · Cited by 2
AntigenBoost: enhanced mRNA-based antigen expression through rational amino acid substitution
Gao, Y., Zhu, S., Li, H., Hao, X., Chen, W., Pan, D., & Qian, Z. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae468 · Cited by 2
Next Generation RNA/Protein‐Carrying Vector With Pleiotropic Activity
Nosaka, T., Ohtsuka, J., Ohtsuka, T., & Fukumura, M. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.70008 · Cited by 2
Stabilizing Prefusion SARS-CoV-2 Spike by Destabilizing the Postfusion Conformation
Chakraborty, D., Singh, R., Rajmani, R. S., Kumar, S., Ringe, R. P., & Varadarajan, R. (2025) · Vaccines · doi:10.3390/vaccines13030315 · Cited by 2
A One Health approach to bovine coronavirus vaccine development, using LSDV as a live virus vector
Chineka, N., Whittle, L., Douglass, N., Williamson, A., & Chapman, R. E. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2480891 · Cited by 2
A Chimeric Virus-Like Particle Vaccine Presenting an Immunodominant Epitope of gB Elicited Potent Neutralizing Antibodies against EBV Infection In Vitro and In Vivo
Zhong, L., Zhang, W., Xiao, R., He, H., Wu, Q., Hong, J., Zeng, M., Zhao, Q., Zheng, Q., Chen, Y., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c00701 · Cited by 2
Recent advances in vaccines and diagnostics against Middle East respiratory syndrome coronavirus
Lee, K., & Nam, J. H. (2020) · Acta Virologica · doi:10.4149/av_2020_208 · Cited by 2
Biophysical and structural characterizations of the effects of mutations on the structure–activity relationships of SARS-CoV-2 spike protein
Yu, P., Yang, T., & Hsu, S. D. (2022) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2022.07.013 · Cited by 2
Bioinformatics Analysis on Potential Anti-Viral Targets Against Spike Protein of MERS-CoV
Li, Y., Gao, H., Xiao, Y., Weng, T.-H., Yu, D.-S., Hu, C. W., Yao, H., & Li, L. (2018) · International Conference on Information Technology in Medicine and Education · doi:10.1109/itme.2018.00026 · Cited by 2
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): Epidemiology and Vaccinology in Nigeria
Adesola, R. O., Oladele, O. E., Tajudeen, A. O., Ogundepo, O., & Dinesh, M. (2021) · International Journal of Travel Medicine and Global Health · doi:10.34172/ijtmgh.2021.10 · Cited by 2
Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies
Qiu, H., Yuan, X.-Y., Cabral, T. M., Manguiat, K., Robinson, A., Wood, H., Grant, C., McQueen, P., Westmacott, G., Beniac, D. R., et al. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105206 · Cited by 4
Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases
Xu, Z., Ho, M., Bordoloi, D., Kudchodkar, S. B., Khoshnejad, M., Giron, L. B., Zaidi, F. I., Jeong, M., Roberts, C. C., Park, Y. K., et al. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1884-4_11 · Cited by 2
Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization
Hauser, B. M., Sangesland, M., Lam, E. C., Feldman, J. E., Balazs, A. B., Lingwood, D., & Schmidt, A. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.902260 · Cited by 2
THE GORDON WILSON LECTURE: RAPID COVID-19 VACCINE DEVELOPMENT AND THE FUTURE OF VACCINOLOGY.
Graham, B. S. (2023) · PubMed Central · Cited by 2
Self-citation
Innovation-driven trend shaping COVID-19 vaccine development in China
Zhang, Y., Zhao, Y., Liang, H., Xu, Y. M., Zhou, C., Yao, Y., Wang, H., & Yang, X. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1034-6 · Cited by 2
O-glycosylation of SARS-CoV-2 spike protein by host <?A3B2 pi6?>O-glycosyltransferase strengthens its trimeric structure
Xu, Z., Zhang, H., Tian, J., Ku, X., Wei, R., Hou, J., Zhang, C., Yang, F., Zou, X., Yang, L., et al. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024127 · Cited by 2
Recent Update of COVID-19 Vaccines
Jadaan, S. A., & Khan, A. W. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2022.045 · Cited by 2
Deciphering the Protein Motion of S1 Subunit in SARS-CoV-2 Spike Glycoprotein Through Integrated Computational MethodsPreprint
Tian, H., & Tao, P. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2004.05256 · Cited by 2
CoV3D: A database and resource for high resolution coronavirus protein structuresPreprint
Gowthaman, R., Guest, J. D., Yin, R., Adolf-Bryfogle, J., Schief, W. R., & Pierce, B. G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.12.091983 · Cited by 2
Vacunas para COVID19: las lecciones de un triunfo de la ciencia biomédica
Gómez‐Marín, J. E. (2021) · Infectio · doi:10.22354/in.v25i3.936 · Cited by 2
Why and How Coronavirus Has Evolved to Be Uniquely Contagious, with Uniquely Successful Stable VaccinesPreprint
Moret, M. A., Zebende, G. F., & Phillips, J. C. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2107.07047 · Cited by 2
Production and secretion of functional full-length SARS-CoV-2 spike protein in Chlamydomonas reinhardtiiPreprint
Kiefer, A. M., Niemeyer, J., Probst, A., Erkel, G., & Schroda, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.13.472433 · Cited by 2
Extensive in vitro and in vivo protein translation via in situ circularized RNAsPreprint
Kumar, A., Palmer, N. D., Miyasaki, K. F., Finburgh, E. N., Xiang, Y., Portell, A. J., Dailamy, A., Suhardjo, A., Chew, W. L., Kwon, E. J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.11.480072 · Cited by 1
Would It Be Possible to Stabilize Prefusion SARS-COV-2 Spikes with Ligands?Preprint
Coll, J. M. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13453919.v1 · Cited by 2
Cryo-Electron Microscopy (CEM) Structures of Viruses
Chmielewski, D., & Chiu, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814515-9.00071-0 · Cited by 2
The post-COVID-19 population has a high prevalence of crossreactive antibodies to spikes from all Orthocoronavirinae generaPreprint
Singh, G., Abbad, A., Kleiner, G., Srivastava, K., Gleason, C., PARIS Study Group, Carreño, J. M., Simon, V. R., & Krammer, F. (2023) · medRxiv · doi:10.1101/2023.08.01.23293522 · Cited by 2
Design, Structure, and Immunogenicity of a Soluble Prefusion-stabilized EBV gB AntigenPreprint
McCool, R. S., Acreman, C. M., Powell, A. E., Picucci, S. I., Stieh, D. J., Huynh, J., Caruso, H., Park, S., O’Rear, J., Chen, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.19.654955 · Cited by 2
Self-citation
Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody ResponsesPreprint
Dzuvor, C. K. O., Moak, S. P., McManus, L. R., Thomas, A., Dzordzorme, A. E., Kim, T., Joseph, J., Foley, V., Gordon, I. J., Novik, L., et al. (2025) · Research Square · doi:10.1101/2025.10.01.679649 · Cited by 2
Self-citation
Molecular basis of pathogenicity of the recently emerged FCoV-23 coronavirusPreprint
Tortorici, M. A., Choi, A., Gibson, C. A., Lee, J., Brown, J. T., Stewart, C., Joshi, A., Harari, S., Willoughby, I., Treichel, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.25.607996 · Cited by 2
Immunogenicity and Protective Efficacy of a SARS-CoV-2 mRNA Vaccine Encoding Secreted Non-Stabilized Spike Protein in Mice
Prompetchara, E., Ketloy, C., Alameh, M.-G., Tarakhet, K., Kaewpang, P., Yostrerat, N., Pitakpolrat, P., Buranapraditkun, S., Manopwisedcharoen, S., Thitithanyanont, A., et al. (2022) · doi:10.1101/2022.09.07.506878 · Cited by 1
Pathogenesis and Immunity of SARS-CoV-2 and Vaccination Programs Against COVID-19
Paschall, A. V., & Avci, F. Y. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839162572-00112 · Cited by 1
Effect of proline content and histidine ligation on the dynamics of Ω-loop D and the peroxidase activity of iso-1-cytochrome c
Martin, W. J., McClelland, L. J., Nold, S. M., Boshae, K. L., & Bowler, B. E. (2023) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2023.112474 · Cited by 1
Heterologous Sarbecovirus Receptor Binding Domains as Scaffolds for SARS-CoV-2 Receptor Binding Motif Presentation
Hauser, B. M., Sangesland, M., Lam, E. C., Denis, K. S., Sheehan, M. L., Vu, M. L., Cheng, A. H., Sordilla, S., Thornlow, D. N., Almawi, A. W., et al. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00483 · Cited by 1
Comparison of N- and O-Glycosylation on Spike Glycoprotein 1 of SARS-CoV-1 and MERS-CoV
Tian, Y., & Cipollo, J. F. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00716 · Cited by 2
SARS-CoV-2 Receptor Binding Domain (RBD) Protein–Protein Conjugate Induces Similar or Better Antibody Responses as Spike mRNA in Rhesus Macaques
Scaria, P. V., Rowe, C. G., Košík, I., Hu, Z., Renn, J. P., Alani, N., Kemanli, P., Orr-Gonzalez, S., Lambert, L., Adeyemi, K., et al. (2025) · Vaccines · doi:10.3390/vaccines13060648 · Cited by 2
Systemic and Mucosal Humoral Immune Responses to Lumazine Synthase 60-mer Nanoparticle SARS-CoV-2 Vaccines
Cheng, C., Boyington, J. C., Sarfo, E. K., Liu, C., Parchment, D. K., Biju, A., Corrigan, A. R., Wang, L., Shi, W., Zhang, Y., et al. (2025) · Vaccines · doi:10.3390/vaccines13080780 · Cited by 1
Self-citation
Interprotomer crosstalk in mosaic viral glycoprotein trimers provides insight into polyvalent immunogen co-assembly
Chen, C., Lovendahl, K. N., Overbaugh, J. M., & Lee, K. K. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013143 · Cited by 1
Current Status and Challenges of Vaccine Development for Seasonal Human Coronaviruses
Zhang, B., Liu, Y., Chen, T., Lai, J., Liu, S., Liu, X., Zhu, Y., Rao, H., Peng, H., & Ma, X. (2025) · Vaccines · doi:10.3390/vaccines13111168 · Cited by 2
Development of a recombinant membrane protein ELISA for analyzing antibody responses against SARS-CoV-2 envelope proteins
Chabot, S., Malik, T., Saye, L., Košíková, M., Kang, H., Ye, Z., Memoli, M. J., Major, M. E., Gier, J. D., & Daniels, R. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110974 · Cited by 1
Experimental and computational approaches to adaptive viral evolution: Linking molecular variation to phenotypic outcomes
Huang, Y., Ou, Z., Xue, X., Zhou, H., & Xiao, K. (2025) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2025.107379 · Cited by 1
Structure-based design of soluble prefusion-stabilized herpes simplex virus type 2 glycoprotein B antigens
Sponholtz, M. R., Ma, D., Ndashimye, E., Byrne, P. O., Shu, Y., Warren, C., Thambi, N., McCool, R. S., Slein, M. D., Johnson, N. V., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117936 · Cited by 1
Self-citation
The value of virological research in wildlife
Lowen, A. C., Runstadler, J. A., & Lakdawala, S. S. (2026) · mBio · doi:10.1128/mbio.03616-25 · Cited by 1
An oral Eimeria-vectored vaccine induces protective immunity against chicken infectious anemia
Liao, Y., Wang, L., Shi, Y., Liang, L., Liang, R., Ding, J., Song, X., & Tang, X. (2026) · npj Vaccines · doi:10.1038/s41541-026-01416-w · Cited by 1
Self-citation
Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants
Zost, S. J., Suryadevara, N., Williamson, L. E., Scheaffer, S. M., Binshtein, E., Buchman, C. D., Johnson, N. V., Catanzaro, N., Ravera, S., Chapman, N. S., et al. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02282-x · Cited by 3
Self-citation
Conformational dynamics of SARS-CoV-2 spike on a membrane reveals the allosteric effects of furin cleavage and the D614G mutation
Shoemaker, S. R., Luo, M., Dam, K.-M. A., Pak, J. E., Hoffmann, M. A. G., & Marqusee, S. (2026) · Science Advances · doi:10.1126/sciadv.adx5178 · Cited by 4
Establishment of a Neonatal Natural Transmission Model for Cytomegalovirus Vaccine Development
Jihad, T., Chi, X. S., He, Z., Lee, K. P., Needle, E., Loschko, J., Goymer, J., Wang, H., Boigard, H., Robertson, C., et al. (2026) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiag170 · Cited by 1
AI-guided prefusion stabilization of the human coronavirus OC43 spike protein enables universal embecovirus antigen design
Melchers, J. M., Juraszek, J., Hulswit, R. J. G., van Overveld, D., Le, L., van Kuppeveld, F. J. M., Hurdiss, D. L., Bosch, B., Langedijk, J. P. M., & Bakkers, M. J. G. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1013998 · Cited by 1

Authors: Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., Kong, W.-P., Andres, E. L., Kettenbach, A. N., Denison, M. R., Chappell, J. D., Graham, B. S., Ward, A. B., & McLellan, J. S.
Affiliations: Scripps Research Institute (US)
Dartmouth College (US)
National Institute of Allergy and Infectious Diseases (US)
Vanderbilt University Medical Center (US)
Vanderbilt University (US)
Corresponding author: Pallesen, Jesper
Wang, Nianshuang
Corbett, Kizzmekia S.
Ward, Andrew B.
McLellan, Jason S.
ORCID: Pallesen, Jesper
Wang, Nianshuang
Corbett, Kizzmekia S.
Wrapp, Daniel
Kirchdoerfer, Robert N.
Turner, Hannah L.
Cottrell, Christopher A.
Wang, Lingshu
Shi, Wei
Kong, Wing-Pui
Kettenbach, Arminja N.
Denison, Mark R.
Chappell, James D.
Graham, Barney S.
Ward, Andrew B.
McLellan, Jason S.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2017-08-14
Volume: 114
Issue: 35
Pages: E7348-E7357
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1707304114
PMC: PMC5584442
OpenAlex: W2750464792
Cited by: 1,073
References: 89
Citations by year: 2026: 48 · 2025: 75 · 2024: 98 · 2023: 127 · 2022: 174 · 2021: 275 · 2020: 220 · 2019: 31 · 2018: 17 · 2017: 6
FWCI: 57.66
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.pnas.org/site/misc/userlicense.xhtml (vor)
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
Funders: HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI127521)
HHS | NIH | National Institute of General Medical Sciences (P20GM113132)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI005125)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords: MERS-CoV, spike protein, structure-based vaccine design, neutralizing antibodies, receptor binding domain, receptor recognition, membrane fusion mechanism, coronavirus vaccines
MeSH terms: Animals, Antibodies, Viral, Coronaviridae, Humans, Immunoglobulin G, Mice, Inbred BALB C, Protein Binding, Protein Conformation, Receptors, Virus, Structure-Activity Relationship, Vaccination, Viral Vaccines, Coronavirus Infections, Crystallography, X-Ray, Immunity, Humoral, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus, Middle East Respiratory Syndrome Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks